Tags

Type your tag names separated by a space and hit enter

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Clin Infect Dis. 2002 Apr 01; 34(7):991-1001.CI

Abstract

The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to </= 400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia.

Authors+Show Affiliations

University of California, Los Angeles School of Medicine, Departments of Pediatrics and Molecular and Medical Pharmacology, Los Angeles, CA, 90095, USA. pkrogstad@mednet.ucla.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

11880966

Citation

Krogstad, Paul, et al. "Nucleoside-analogue Reverse-transcriptase Inhibitors Plus Nevirapine, Nelfinavir, or Ritonavir for Pretreated Children Infected With Human Immunodeficiency Virus Type 1." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 34, no. 7, 2002, pp. 991-1001.
Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34(7):991-1001.
Krogstad, P., Lee, S., Johnson, G., Stanley, K., McNamara, J., Moye, J., Jackson, J. B., Aguayo, R., Dieudonne, A., Khoury, M., Mendez, H., Nachman, S., & Wiznia, A. (2002). Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 34(7), 991-1001.
Krogstad P, et al. Nucleoside-analogue Reverse-transcriptase Inhibitors Plus Nevirapine, Nelfinavir, or Ritonavir for Pretreated Children Infected With Human Immunodeficiency Virus Type 1. Clin Infect Dis. 2002 Apr 1;34(7):991-1001. PubMed PMID: 11880966.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. AU - Krogstad,Paul, AU - Lee,Sophia, AU - Johnson,George, AU - Stanley,Kenneth, AU - McNamara,James, AU - Moye,John, AU - Jackson,J Brooks, AU - Aguayo,Rosaura, AU - Dieudonne,Arry, AU - Khoury,Margaret, AU - Mendez,Hermann, AU - Nachman,Sharon, AU - Wiznia,Andrew, AU - ,, Y1 - 2002/02/27/ PY - 2001/06/11/received PY - 2001/09/26/revised PY - 2002/3/7/pubmed PY - 2002/3/20/medline PY - 2002/3/7/entrez SP - 991 EP - 1001 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin. Infect. Dis. VL - 34 IS - 7 N2 - The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to </= 400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/11880966/Nucleoside_analogue_reverse_transcriptase_inhibitors_plus_nevirapine_nelfinavir_or_ritonavir_for_pretreated_children_infected_with_human_immunodeficiency_virus_type_1_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/338814 DB - PRIME DP - Unbound Medicine ER -